Evidence map›Paper›PMID 24791013›Full record

ArticleJournal of cancer research and therapeutic oncology2013

Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.

Richard M Gallo, Ianthe N Bryant, Christopher P Mill, Steven Kaverman, David J Riese

Open access · diamondAbstract read
In one paragraph

Article in Journal of cancer research and therapeutic oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Richard M GalloDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy & Purdue University Center for Cancer Research, West Lafayette, IN 47907, USA ; Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46206 USA.
Ianthe N BryantDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy & Purdue University Center for Cancer Research, West Lafayette, IN 47907, USA.
Christopher P MillDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy & Purdue University Center for Cancer Research, West Lafayette, IN 47907, USA ; Department of Pharmacal Sciences, Auburn University Harrison School of Pharmacy, Auburn, AL 36849-5501 USA.
Steven KavermanDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy & Purdue University Center for Cancer Research, West Lafayette, IN 47907, USA.
David J RieseDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy & Purdue University Center for Cancer Research, West Lafayette, IN 47907, USA ; Department of Pharmacal Sciences, Auburn University Harrison School of Pharmacy, Auburn, AL 36849-5501 USA.
Purdue University West Lafayette · US

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI John Tesmer · 1985 to 2026
$43.4M
Regulation of ErbB4 Signaling by Neuregulin IsoformsR01CA114209 · NCI · PURDUE UNIVERSITY · PI RIESE, DAVID J. · 2006 to 2010
$1.2M
NCI NIH HHS P30 CA023168NCI NIH HHS R01 CA114209
6 · The paper itself

Abstract

ErbB4 (HER4) is a member of the ErbB family of receptor tyrosine kinases, which includes the Epidermal Growth Factor Receptor (EGFR/ErbB1), ErbB2 (HER2/Neu), and ErbB3 (HER3). Mounting evidence indicates that ErbB4, unlike EGFR or ErbB2, functions as a tumor suppressor in many human malignancies. Previous analyses of the constitutively-dimerized and -active ErbB4 Q646C mutant indicate that ErbB4 kinase activity and phosphorylation of ErbB4 Tyr1056 are both required for the tumor suppressor activity of this mutant in human breast, prostate, and pancreatic cancer cell lines. However, the cytoplasmic region of ErbB4 possesses additional putative functional motifs, and the contributions of these functional motifs to ErbB4 tumor suppressor activity have been largely underexplored. Here we demonstrate that ErbB4 BH3 and LXXLL motifs, which are thought to mediate interactions with Bcl family proteins and steroid hormone receptors, respectively, are required for the tumor suppressor activity of the ErbB4 Q646C mutant. Furthermore, abrogation of the site of ErbB4 cleavage by gamma-secretase also disrupts the tumor suppressor activity of the ErbB4 Q646C mutant. This last result suggests that ErbB4 cleavage and subcellular trafficking of the ErbB4 cytoplasmic domain may be required for the tumor suppressor activity of the ErbB4 Q646C mutant. Indeed, here we demonstrate that mutants that disrupt ErbB4 kinase activity, ErbB4 phosphorylation at Tyr1056, or ErbB4 cleavage by gamma-secretase also disrupt ErbB4 trafficking away from the plasma membrane and to the cytoplasm. This supports a model for ErbB4 function in which ErbB4 tumor suppressor activity is dependent on ErbB4 trafficking away from the plasma membrane and to the cytoplasm, mitochondria, and/or the nucleus.

Indexed as

ErbB4/HER4Protein TraffickingSignal TransductionTumor Suppressor

Identifiers

PMID24791013
PMCPMC4002051
OpenAlexW2144054831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.